Skip to Content
AP-National

Denmark’s Novo Nordisk and South Africa’s Aspen sign a deal to produce insulin for African patients

By
Published 2:46 AM

By GERALD IMRAY
Associated Press

CAPE TOWN, South Africa (AP) — Danish pharmaceutical company Novo Nordisk has signed a deal with South Africa’s Aspen Pharmacare to produce human insulin specifically for diabetes patients in Africa where there is a dire need for the life-saving treatment. The Africa Centers for Disease Control and Prevention welcomed the move Wednesday, saying it would “greatly impact the fight against diabetes” in Africa. Novo Nordisk has contracted Aspen to convert insulin into finished doses at its plant in Gqeberha, South Africa. They project the production of 16 million vials in 2024, the yearly amount needed to treat 1.1 million patients in Africa, and an increase to enough insulin to treat 4.1 million diabetes patients on the continent annually by 2026.

Article Topic Follows: AP-National

Jump to comments ↓

Associated Press

BE PART OF THE CONVERSATION

KION 46 is committed to providing a forum for civil and constructive conversation.

Please keep your comments respectful and relevant. You can review our Community Guidelines by clicking here

If you would like to share a story idea, please submit it here.

Skip to content